Keystone EC, Rampakakis E, Movahedi M, et al. - This study intended to compare the rate of real-world “nonresponse” to first anti-TNF as reported by treating physicians to the nonresponse rate per accepted definitions and recommended treat-to-target strategies. Researchers enrolled individuals from the Biologic Treatment Registry Across Canada (BioTRAC) and Ontario Best Practices Research Initiative (OBRI) registries who were taking their first anti-TNF, with ≥ 1 followup visit. This study included 736 BioTRAC and 640 OBRI individuals. The results of this study displayed that physician-reported 1ry nonresponse was more associated with non-achievement of Disease Activity Score based on erythrocyte sedimentation rate low disease activity erythrocyte sedimentation rate or Clinical Disease Activity IndexI  low disease activity, whereas 2ry nonresponse with actual time of discontinuation. Future research is required to clarify the importance of response and type of response to the initial anti-TNF in distinguishing individuals most likely to benefit from a second biologic agent treatment.